Related Experiment Videos
ARF-BP1 as a potential therapeutic target.
D Chen1, C L Brooks, W Gu
1Institute for Cancer Genetics, Department of Pathology, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Ave, New York, NY 10032, USA.
British Journal of Cancer
|April 28, 2006
Summary
ARF-BP1, an E3 ubiquitin ligase, regulates p53 stability and apoptosis. Inhibiting ARF-BP1 offers a promising new cancer therapy strategy, effective even in p53-deficient tumors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9) is a recently identified HECT domain-containing E3 ubiquitin ligase.
- ARF-BP1 interacts with tumor suppressors ARF and p53.
- The E3 ubiquitin ligase activity of ARF-BP1 is regulated by ARF.
Purpose of the Study:
- To review the role of ARF-BP1 in cancer.
- To explore ARF-BP1 as a potential therapeutic target.
Main Methods:
- Literature review of ARF-BP1 function.
- Analysis of ARF-BP1 interactions with ARF and p53.
- Investigation of ARF-BP1's impact on p53 stability and apoptosis.
Main Results:
- ARF inhibits the ubiquitin ligase activity of ARF-BP1.
- Inactivation of ARF-BP1 leads to p53 stabilization and apoptosis induction.
- ARF-BP1 inactivation suppresses tumor growth in p53-null and mutant p53 cancer cells.
Conclusions:
- ARF-BP1 is a critical regulator of p53.
- Targeting ARF-BP1 represents a novel therapeutic strategy for various cancers, irrespective of p53 status.